Phase 1 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are aged 18 to 75 years old and have been diagnosed with dilated cardiomyopathy (a condition where the heart becomes enlarged and cannot pump blood properly)
- People who previously received a single infusion of a specific immune-modifying cell therapy called iCDC, and whose heart function improved at first but then declined back to pre-treatment levels by 6 months after that first treatment
- People whose heart is still not pumping well enough, specifically with a heart pumping strength (LVEF) below 35%, significant heart failure symptoms rated as Class III or IV on a standard medical scale, and a disease severity rating falling within a specific middle range on another standard heart failure scale (INTERMACS profile 3–6)
- People who are able to verbally show they understand the risks, benefits, and other treatment options, and are willing to take part; either the person themselves or their legal representative must sign a written consent form before enrolling
- People whose blood test results meet minimum thresholds for red blood cell percentage, a type of white blood cell count, and platelet count (confirm with trial site for exact values)
Who may not be able to join:
- People with severe kidney failure, those currently on kidney dialysis, or those with a specific blood marker for kidney function above a certain level
- People with significantly elevated liver enzyme levels or a liver-related blood marker above a certain threshold, which may suggest liver damage
- People with certain active infections at the time of screening, including active hepatitis B with a detectable virus level above a set amount, hepatitis C, syphilis, HIV, or any other serious uncontrolled infection caused by fungus, bacteria, viruses, or other organisms
- People experiencing severe instability in how the heart is pumping blood around the body, such as being in shock
- People with known reasons they should not receive the study treatment or undergo the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xinyang Hu, PhD, Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Phone: 86-18868112006
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The proportion of subjects with Dose-limiting toxicity (DLT); Incidence of treatment-emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.